Bexagliflozin
Introduction
Name
- Bexagliflozin.
Class of drug
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor antidiabetic agent.
Description
Chemical name
- (2S,3R,4R,5S,6R)-2-(4-chloro-3-{[4-(2-cyclopropoxyethoxy)phenyl]methyl}phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
Molecular formula
- C24H29ClO7
Molecular weight
- 464.9
Physical properties
- Speckled white, brown, or tan pentagonal tablets (chewable/flavored).
Storage requirements
- Store at or below 25°C/77°F.
Uses
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Administration
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Pharmacokinetics
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Precautions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Adverse reactions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Further Reading
Publications
Refereed papers
- Hadd MJ, Bienhoff SE, Little SE et al (2023) Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. J Vet Intern Med. 37 (3), 915-924. PubMed
Other sources of information
- Elanco (2022) Bexacat® Bexagliflozin Tablets Package Insert. Website: www.elancolabels.com
- FDA (2022) Bexagliflozin Freedom of Information Summary. Website: www.animaldrugsatfda.gov